Patent US3980770A successfully refreshed from Google Patents.
US3980770A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymerization products containing amino groups useful in serum cholesterol level control
Assignee: Pfizer Health AB
•
Filing: 1974-12-05
•
Granted: 1976-09-14
•
Expires: 1994-12-05
Abstract
Abstract A pharmaceutical product containing amino groups, which product: A. is comprised of residues of one or more diamines of the general formula H.sub.2 N.CH.sub.2. phenylene.CH.sub.2.NH.sub.2 (I) which residues are interconnected by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprise straight or branched aliphatic, saturated hydrocarbon chains substituted with one or more hydroxyl groups and containing 3-30 carbon atoms, preferably 3-16 carbon atoms and which are optionally broken by one or more oxygen atoms, the amino groups being present in a free form or in the form of (the cation portion of) a non-toxic salt, and B. is insoluble in water or other solvents, but capable of swelling in water to gel form, 1 g of the dry product in the form of an HCl salt in the presence of water swelling to at least 5 ml and to at most 50 ml, preferably to at least 5 ml and to at most 25 ml, and C. is in grain form having a particle size substantially within the range of 1 to 1000 μ, preferably 10 to 800 μ, and D. has an ion-exchange capacity within the range of 0.2 to 1 milliequivalents chloride ions, preferably 0.3 to 0.9 milliequivalents chloride ions, per 100 mg of dry gel, A method for its preparation and use for lowering the cholesterol content of the blood of mammals and birds.
Inventors
- 👤 Bjorn G.-A. Ingelman
- 👤 Bernt J. Lindberg
- 👤 Jan G. Rosengren
- 👤 Dag E. S. Campbell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 13:59
CPC Classifications
B; B01; B01J; B01J41/00; B01J41/08; B01J41/12; B01J41/14; A; A61; A61K; A61K31/00; A61K31/74; A61K31/785; C; C08; C08G; C08G59/00; C08G59/18; C08G59/40; C08G59/50; C08G59/5033
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
222 words
A pharmaceutical product for oral administration to mammals and birds having an elevated serum cholesterol level in their blood, which product contains a physiologically acceptable carrier and a cholesterol lowering amount of a waterinsoluble polymer containing amino groups and which polymer a. contains residues of at least one diamine of the general formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2.NH.sub.2 (I) which residues are interconnected by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprise straight or branched aliphatic, saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water, but capable of swelling in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of water swelling to a volume within the range of 5 to 50 ml, inclusive, and c. is in grain form having a particle size within the range of 1 to 1000 μ, and d. has an ion-exchange capacity within the range of 0.2 to 1 milliequivalent chloride ions per 100 mg of dry gel.
Claim 2
Dependent Claim
222 words
A pharmaceutical product for oral administration to mammals and birds having an elevated serum cholesterol level in their blood, which product contains a physiologically acceptable carrier and a cholesterol lowering amount of a waterinsoluble polymer containing amino groups and which polymer a. contains residues of at least one diamine of the general formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2.NH.sub.2 (I) which residues are interconnected by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprise straight or branched aliphatic, saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water, but capable of swelling in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of water swelling to a volume within the range of 5 to 50 ml, inclusive, and c. is in grain form having a particle size within the range of 1 to 1000 μ, and d. has an ion-exchange capacity within the range of 0.2 to 1 milliequivalent chloride ions per 100 mg of dry gel.
Claim 3
Dependent Claim
15 words
A product according to claim 1 which contains 0.5 - 30 gms of said polymer.
Claim 4
Dependent Claim
20 words
A pharmaceutical product according to claim 1, wherein the polymer containing amino groups is in the form of spherical granules.
Claim 5
Dependent Claim
32 words
A pharmaceutical product according to claim 1, wherein the three-dimensional network of the polymer allows bile acids and salts thereof to penetrate thereinto when the product is in a water swollen state.
Claim 6
Dependent Claim
37 words
A pharmaceutical product according to claim 1, wherein 1 g of the dry polymer in the form of the hydrochloride in the presence of water swells to at least 5 ml and to at most 25 ml.
Claim 7
Dependent Claim
26 words
A pharmaceutical product according to claim 1, wherein the polymer is in grain form having a particle size within the range of 10 to 800 μ.
Claim 8
Dependent Claim
30 words
A pharmaceutical product according to claim 1, wherein the polymer has an ion-exchange capacity within the range of 0.3 to 0.9 milliequivalent chloride ions per 100 mg of dry gel.
Claim 9
Dependent Claim
222 words
A pharmaceutical product for oral administration to mammals and birds having an elevated serum cholesterol level in their blood, which product contains a physiologically acceptable carrier and a cholesterol lowering amount of a waterinsoluble polymer containing amino groups and which polymer a. contains residues of one or more diamines of the formula H.sub.2 H.CH.sub.2.phenylene.CH.sub.2.NH.sub.2 (I) which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. is in grain form having a particle size within the range of 10 to 800 μ, and d. has an ion-exchange capacity within the range of 0.3 to 0.9 milliequivalent chloride ions per 100 mg of dry gel.
Claim 10
Dependent Claim
222 words
A pharmaceutical product for oral administration to mammals and birds having an elevated serum cholesterol level in their blood, which product contains a physiologically acceptable carrier and a cholesterol lowering amount of a waterinsoluble polymer containing amino groups and which polymer a. contains residues of one or more diamines of the formula H.sub.2 H.CH.sub.2.phenylene.CH.sub.2.NH.sub.2 (I) which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. is in grain form having a particle size within the range of 10 to 800 μ, and d. has an ion-exchange capacity within the range of 0.3 to 0.9 milliequivalent chloride ions per 100 mg of dry gel.
Claim 11
Dependent Claim
15 words
A product according to claim 8 which contains 0.5 - 30 g of said polymer.
Claim 12
Independent Claim
229 words
A method of lowering the cholesterol content of the blood of mammals and birds having an elevated serum cholesterol level, said method consisting essentially of the oral administration of a physiologically acceptable carrier and a cholesterol lower amount of a polymer containing amino groups and which polymer a. is formed of residues of one or more diamines of the formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2. NH.sub.2 which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in either a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. comprises grains having a particle size within the range of 1 to 1000 μ, and d. has a ion-exchange capacity within the range of 0.2 to 1 milliequivalent chloride ions per 100 my of dry gel.
Claim 13
Independent Claim
229 words
A method of lowering the cholesterol content of the blood of mammals and birds having an elevated serum cholesterol level, said method consisting essentially of the oral administration of a physiologically acceptable carrier and a cholesterol lower amount of a polymer containing amino groups and which polymer a. is formed of residues of one or more diamines of the formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2. NH.sub.2 which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by one to four oxygen atoms, the amino groups being present in either a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. comprises grains having a particle size within the range of 1 to 1000 μ, and d. has a ion-exchange capacity within the range of 0.2 to 1 milliequivalent chloride ions per 100 my of dry gel.
Claim 14
Dependent Claim
21 words
A method according to claim 10 wherein said polymer is administered in an amount of 0.5 to 30 g per day.
Claim 15
Dependent Claim
21 words
A method according to claim 10 wherein said polymer is administered in an amount of 3 to 15 g per day.
Claim 16
Independent Claim
230 words
A method of lowering the cholesterol content of the blood of mammals and birds having an elevated serum cholesterol level said method consisting essentially of the oral administration of a physiologically active carrier and a cholesterol lowering amount of a polymer containing amino groups and which polymer a. is formed of residues of one or more diamines of the formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2 NH.sub.2 (I) which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by 1 to 4 oxygen atoms, the amino groups being present in either a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. comprises grains having a particle size within the range of 10 to 800 μ, and d. has an ion-exchange capacity within the range of 0.3 to 0.9 milliequivalent chloride ion per 100 mg of dry gel.
Claim 17
Independent Claim
230 words
A method of lowering the cholesterol content of the blood of mammals and birds having an elevated serum cholesterol level said method consisting essentially of the oral administration of a physiologically active carrier and a cholesterol lowering amount of a polymer containing amino groups and which polymer a. is formed of residues of one or more diamines of the formula H.sub.2 N.CH.sub.2.phenylene.CH.sub.2 NH.sub.2 (I) which residues are held together by bridges between the residues to form a three-dimensional network, the bridges being bound to nitrogen atoms in the residues (I) and comprising straight or branched aliphatic saturated hydrocarbon chains substituted with one to four hydroxyl groups and containing 3 - 16 carbon atoms, and which are unbroken or broken by 1 to 4 oxygen atoms, the amino groups being present in either a free form or in the form of the cation portion of a non-toxic salt, and b. is insoluble in water but swellable in water to a gel, 1 g of the dry polymer in the form of the hydrochloride in the presence of the water swelling to a volume within the range of from 5 to 50 ml, inclusive, and c. comprises grains having a particle size within the range of 10 to 800 μ, and d. has an ion-exchange capacity within the range of 0.3 to 0.9 milliequivalent chloride ion per 100 mg of dry gel.
Claim 18
Dependent Claim
22 words
A method according to claim 13 wherein said polymer is administered in an amount of between 0.5 to 30 g per day.
References Cited (Backward Citations)
CA634985A
Cited
US2106486A
Cited
US2582849A
Cited
US2469683A
Cited
US3383281A
Cited
US3265663A
Cited
FR1488152A
Cited
US3627872A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-09-14 | 1980-03-15 | 1980-09-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-09-14 | 1984-03-15 | 1984-09-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-09-14 | 1988-03-15 | 1988-09-14 | $7700.00 | Window Closed / Lapsed |